The prevalence of depressive and anxious symptoms among gout patients was higher than healthy individuals. Education, disability, tophi and HRQoL were important risk factors linked to this disorder in Chinese gout population. These findings suggested medical personnel should pay more attention to the psychological health of gout patients and make objective interventions to relieve their depression and anxiety, especially those with low education level, more than two tophi, severe disability, and poor HRQoL. Acknowledgements: This study was supported by Grants from the Chinese National Natural Science Foundation (no. 81671616 and 81471603 Background: Acute gout is usually associated with a decrease in serum uric acid (SUA) level but the mechanism responsible for this phenomenon remains unclear. Objectives: We aimed to investigate relationships between changes in SUA level, urinary excretion of uric acid and biochemical markers during gout attack. Methods: SUA, eGFR (estimated glomerular filtration rate), serum CRP level and urinary excretion of UA, expressed as fractional excretion of UA (FeUA), from 35 ULT (urate-lowering therapy)-free and diuretic-free gout patients were prospectively measured during acute gout attack (Tc) and intercritical (Tic) phase. In 11 patients, data were available after achievement of SUA target (Tt) (<360 μmol/l) under ULT. Demographics data and waist circumference (WC) were collected. Data are expressed as mean ± SD. Results: There were 32 men, mean age 57.9 years, mean body mass index 28.6 kg/m 2 , and mean waist circumference 104 cm. Overall 17.1% had type 2 diabetes, 37.1% dyslipidemia, 54.3% hypertension, 34.4% obesity, 74.3% abdominal obesity and 51.4% chronic kidney disease (CKD, 31.4% CKD 2 and 20% CKD 3-5). Gout duration was 3.9±6.7 years, 28.6% of patients had tophus and 31.4% gout arthropathy. SUA, eGFR and FeUA values were similar between Tc and Tic phases: SUA: 504.9±79.9 and 507.6±89.7 μmol/l; eGFR: 78.1±28.8 and 81.4±33.8 ml/min/1.73m 2 ; FeUA: 4.90±2.3 and 4.45±3.3%, respectively. Moreover, the FeUA values were identical between Tt, Tic and Tc in 11 patients who achieved SUA target (296.0±37.8 μmol/l) under ULT. CRP levels were higher at Tc (44.8±69.4 mg/dL) than Tic (5.2±3.3 mg/dl) and Tt (4.6±1.2 mg/dl). While mean SUA levels were similar between Tc and Tic, SUA levels were lower in Tc than Tic in 21 patients (mean difference: 56.9±33.7 μmol/l) (figure1). In contrast, 14 patients had a SUA level higher in Tc than in Tic (mean difference: 78.6±71.5 μmol/L) (figure 1). SUA variations between Tc and Tic were not correlated with FeUA modifications in these two groups (p=0.15). Similarly, SUA and FeUA variations were not correlated with CRP variations between Tc and Tic (p=0.29 and p=0.30, respectively).
Conclusions: SUA levels during gout attack can be either higher or lower than SUA during intercritical phase. These variations are linked neither to inflammation level nor to FeUA. It would be interesting to assess the intestinal excretion of uric acid, xanthine oxidase activity and diet intake during these different gout phases. Background: Dual-energy computed tomography (DECT) is advanced imaging modality that shows the deposition of monosodium urate (MSU) crystal in tissue as a color signal. The MSU crystal deposit around the symptomatic joint is considered as positive finding, but the clinical significance of urate deposition around the tendon is still unclear. Objectives: The aim of this study was to compare the clinical characteristics and DECT findings in people with MSU crystal deposition in the joints and people with urate deposition in the tendons. Methods: DECT was performed in 71 patients who complained of recurrent painful swelling of the joints, and 35 of them showed MSU crystal deposition in the joints on DECT. Clinical manifestation and serum uric acid level data were collected. Results: Most of the included patients were middle-aged (mean age 50 years, SD 15) and 67 patients (94%) were male. All patients who had MSU crystal deposition in joints on DECT had a history of typical gout attacks, and 29 patients (81%) had a history of gout attacks among patients with urate deposition only in tendons (p=0.011). The mean uric acid level of patients included in the study was as high as 7.5±2.2 mg/dL. In the highest uric acid level, the absolute value was higher in patients with urate deposition in joints, but there was no statistical significance. The correlation between the gout attack site and the urate deposit sites was 91% in patients with joint involvement, but only 6% in patients without joint involvement (p<0.001). There were 4 patients (11%) who showed gouty erosion without MSU crystal deposition in joints on DECT.
Conclusions:
The MSU crystal deposition in the tendon was not correlated well with clinical features, suggesting that it is more likely to be associated with artifact or asymptomatic hyperuricemia. However, in some patients, MSU crystal deposition may be observed only in the tendon, even with gouty erosion. Therefore, careful interpretation of the DECT results is necessary. Background: The advent of biological treatments has greatly improved the management of chronic inflammatory diseases (CID). However, these biologics increase the risk of infection including the possible development of tuberculosis (TB). Screening of latent tuberculosis infection (LTBI) is therefore necessary prior to their initiation, especially in Tunisia, which is considered as a high-incidence area of TB. Objectives: The aims of this study were to identify the prevalence of LTBI among patients candidate to initiate biologics, to analyze the tolerance of preventive therapy and to detect active TB or conversions of immunodiagnostic tests under biologics. Methods: A retrospective study was conducted, over a period of 14 years (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Patients with CID, candidate to initiate biological treatment, were included. The screening of LTBI was performed according to the national Tunisian guidelines. Clinical data, screening and follow-up information on biological therapy were assessed. Results: A total of 76 patients were enrolled in the study, 32 men and 44 women with a mean age of 66 years . Rheumatoid arthritis (RA) was the most common CID (44%). The diagnosis of LTBI was established in 16 cases (21%). Among them, 3 had a Tuberculin Skin Test (TST) more than 10mm associated with a positive Interferon Gamma Release Assay (IGRA), 11 had only a positive TST, and 2 had only a positive IGRA. One of them had a history of pulmonary TB but adequately treated. All patients with positive screening were considered for preventive treatment. Thirteen (81%) received an association of isoniazid-rifampicin for 3-6 months, and 3 (19%) received isoniazid for 6 months. Toxicity was reported in 4 cases (25%): hepatotoxicity (n=1), dermatologic toxicity (n=1), fever (n=1) and stomachache (n=1). During the follow-up period, no case of reactivation has been reported among patients with LTBI. Out of the 60 patients with negative baseline screening, only 4 have been re-screened (6%) and none had conversions in immunodiagnostic tests. However, among patients who screened negative, one case of active pulmonary TB has been reported in a woman who had an ankylosing spondylitis (AS) and who was receiving infliximab during 22 weeks. She hadn't previous TB history or new TB exposure. Conclusions: Our study showed that the Tunisian recommendations allowed detecting a LTBI in 21% of biologic therapy candidates. The initial screening and the prophylactic treatment improve the safety of these treatments. However, we noted a low rate of re-screening, as the Tunisian guidelines do not recommend
